iX Biopharma cuts loss in FY 2025

The group’s revenue grew by 30% year on year to $7.7m.

iX Biopharma has narrowed its loss to $10.1m for the financial year 2025, compared to a $10.8m loss during the same period last year.

The group’s revenue grew by 30% year on year to $7.7m. Despite weaker consumer spending in Australia, Speciality Pharmaceuticals grew its revenue by 22% driven by strong sales of medicinal cannabis products and services in Australia.

The Nutraceuticals segment also grew more than twofold, primarily from new engagements in the PRC, USA, Europe and the Middle East.

Despite higher revenue, the group’s cost of sales increased due to a different revenue mix and economies of scale.